<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887495</url>
  </required_header>
  <id_info>
    <org_study_id>051427</org_study_id>
    <nct_id>NCT02887495</nct_id>
  </id_info>
  <brief_title>The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)</brief_title>
  <official_title>The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers
      use clinical data and human biospecimens to investigate why scleroderma patients develop
      certain complications from their disease. Patients with confirmed scleroderma, raynauds or
      positive autoantibodies are invited to participate. This research may help us understand how
      to prevent and treat scleroderma and other diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2040</completion_date>
  <primary_completion_date type="Anticipated">July 2034</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rodnan Skin Score</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medsger Severity Score</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Scleroderma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with scleroderma, raynauds, or with positive autoantibodies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Able to give informed consent.

          -  Diagnosed with scleroderma or with positive autoantibodies

        Exclusion Criteria:

          -  &lt; 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria K Shanmugam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viictoria K Shanmugam, MD</last_name>
    <phone>202-741-2488</phone>
    <email>vshanmugam@mfa.gwu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Derek Jones, PhD</last_name>
    <phone>202-994-8567</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Victoria K Shanmugam</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria K Shanmugam, MD</last_name>
      <phone>202-741-2488</phone>
      <email>vshanmugam@mfa.gwu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Derek Jones, PhD</last_name>
      <phone>202-994-8567</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Victoria Shanmugam</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>biorepository</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

